RxDoctor Payments Data

Jennifer Thomas, MD

Family Medicine · Gillette, WYNPI 1093800237

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 29.8% of the total. 2025 is the largest year on record at $291, more than ten times the $14 reported in 2019.

$700in general payments, 2019–2025

Across 37 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$208
  • Novo Nordisk$130
  • Amgen$129
  • AstraZeneca$60
  • Astellas Pharma US Inc$51
  • Lilly USA, LLC$44
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$69399%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$700 in reported general payments places this provider in the 75th percentile of 237 family medicine providers in Wyoming.

See all family medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$53,845
Medicare patients
235
Services billed
1,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$44,226
MounjaroTirzepatide14$15,014
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,803
Admelog SolostarInsulin Lispro11$2,046
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,350
Atorvastatin Calcium73$779
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$674
Levothyroxine Sodium84$631
Omeprazole28$603
Gabapentin25$480
Losartan Potassium65$430
Duloxetine Hcl16$423
Amlodipine Besylate55$400
Lisinopril74$392
Escitalopram Oxalate25$325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$44,22646 claims
Lilly USA, LLCMounjaro$44$15,01414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 237 family medicine providers in Wyoming.

Other family medicine in Gillette

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →